These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18160251)

  • 41. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
    Petrylak DP
    Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What next after hormonotherapy in cancer prostate?
    Parvez T; Al-sisi H; Ibraheim I
    J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
    Johannsen M; Wilke K; Schnorr D; Loening SA
    Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chemotherapy for prostate cancer].
    Rauchenwald M; De Santis M; Fink E; Höltl W; Kramer G; Marei IC; Neumann HJ; Reissigl A; Schmeller N; Stackl W; Hobisch A; Krainer M
    Wien Klin Wochenschr; 2008; 120(13-14):440-9. PubMed ID: 18726672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
    Bradley DA; Hussain M
    Cancer J; 2008; 14(1):15-9. PubMed ID: 18303478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
    Sonpavde G; Sternberg CN
    Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docetaxel in hormone-refractory metastatic prostate cancer.
    McKeage K; Keam SJ
    Drugs; 2005; 65(16):2287-94; discussion 2295-7. PubMed ID: 16266195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Chemotherapy with docetaxel in prostate cancer. A case report].
    Lechevallier E; Culine S; Benchikh El Fegoun A
    Prog Urol; 2010 Mar; 20 Suppl 1():S80-3. PubMed ID: 20493453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
    Harrington JA; Jones RJ
    Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New targeted therapies in hormone-refractory prostate cancer].
    Oudard S; Banu E; Scotte F; Beuzeboc P; Guyader C; Medioni J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F62-8. PubMed ID: 17845995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
    Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
    Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overcoming chemotherapy resistance in prostate cancer.
    Madan RA; Pal SK; Sartor O; Dahut WL
    Clin Cancer Res; 2011 Jun; 17(12):3892-902. PubMed ID: 21680545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
    Ferrero JM
    Bull Cancer; 2005 May; 92(5):425-7. PubMed ID: 15932803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hormone-refractory prostate cancer: where are we going?
    Di Lorenzo G; Autorino R; Figg WD; De Placido S
    Drugs; 2007; 67(8):1109-24. PubMed ID: 17521214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.